Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT07649720
Starting soon Not applicable

NaviCam Patency Capsule to Verify Gastrointestinal Patency

NCT07649720 · tracked via the Priya Life Science USA tracker
Sponsor
AnX Robotica Corp
Phase
Not applicable
Started
2026-06-15
Last updated
2026-06-16

Condition(s) studied

Intestinal StrictureCrohn DiseaseNSAID (Non-Steroidal Anti-Inflammatory Drug) Induced EnteropathyAbdominal Pain

Investigational drug(s) / intervention(s)

NaviCam Patency Capsule

NaviCam Patency Capsule: The NaviCam Patency Capsule is an accessory to the NaviCam capsule and is intended to verify adequate patency of the gastrointestinal tract prior to administration of the NaviCam capsule in patients with known or suspected strictures.

Study summary

Participants included in this study will first swallow a patency capsule and then undergo an abdominal X-ray scan within 30 hours after swallowing the capsule to confirm weather the capsule is still in the body.

Eligibility

Sex
ALL
Min age
22 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients with suspected or known intestinal stricture (with medical history records, physical examination records, and imaging evidence within the last 6 months. * Patients suffering from Crohn's Disease * Patients with long-term use of non-steroidal anti-inflammatory drugs. * Patients with abdominal symptoms related to intestinal stricture. * Patients with chronic inflammatory diseases. * Patients with difficulty with balloon-assisted endoscopy (BAE). * Patients with a history of small bowel obstruction. * Patients with a history of intestinal resection surgery. Exclusion Criteria: * Patients with esophageal obstruction or swallowing disorder diseases. * Patients who are ineligible for surgery or refuse to undergo any abdominal surgery. * Patients with known allergies or other contraindications or intolerance to the medications used in this study. * Patients with pacemakers or other implanted electronic devices such as cochlear implants, magnetic metal drug infusion pumps, neurostimulators. * Pregnant women * Patients currently enrolled in another drug or device clinical trial. * Other conditions deemed unsuitable for inclusion by the investigator.

Primary outcome measure(s)

  • Safety of patency capsule — 30 hours
    The number of patients successfully passing the Patency Capsule within 30 hours compared to the number of patients where the Patency Capsule dissolves in patients with strictures.
  • Efficacy of patency capsule — 30 hours
    The percentage of patients that successfully pass the Patency capsule within 30 hours.

Trial sites (1)

FacilityCityRegionStatus
Digestive Health Services Downers Grove Illinois

More AnX Robotica Corp. trials in the USA

A Post Market Trial Assessing the Accuracy of Normal Mode Reading vs. ProScan Reading With the NaviCam SB System. This is a Comparison of Retrospectively Obtained Capsule Endoscopy Videos With a New AI Reading Tool; no New Interventions Will be Completed. Starting soon

Other trials for the same condition

A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease Active, not recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease Recruiting
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Recruiting
A Study Evaluating the Impact of Regular FODMAP-targeting Digestive Enzyme Blend Use on Gastrointestinal Symptoms in Individuals With Self-Reported Bloating Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07649720 on ClinicalTrials.gov ↗ ← All trials in the USA